Can Losartan (angiotensin II receptor antagonist) 100mg be prescribed twice a day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Losartan 100mg Twice Daily Dosing

Losartan 100mg should not be prescribed twice daily as the FDA-approved maximum daily dose is 100mg once daily for hypertension, with no evidence supporting twice-daily dosing at this maximum strength. 1

FDA-Approved Dosing Guidelines

  • The FDA-approved maximum dose of losartan for hypertension is 100mg once daily 1
  • For hypertension, the usual starting dose is 50mg once daily, which can be increased to a maximum of 100mg once daily as needed to control blood pressure 1
  • For nephropathy in Type 2 diabetic patients, the usual starting dose is 50mg once daily, with potential increase to 100mg once daily based on blood pressure response 1

Evidence from Clinical Guidelines

  • According to the ACC/AHA guidelines, losartan can be administered once or twice daily, but the total daily dose should not exceed 100mg 2
  • The ACC/AHA hypertension guidelines specifically list losartan's usual dose range as 50-100mg/day with a daily frequency of "1 or 2" 2
  • While twice-daily dosing at 50mg per dose (100mg total daily) may provide more consistent trough responses than once-daily dosing at the same total dose, exceeding 100mg total daily is not recommended 1

Special Considerations for Heart Failure

  • For heart failure patients with reduced ejection fraction, the target dose of losartan is 100mg once daily 3
  • The HEAAL trial demonstrated that 150mg daily of losartan (as a single dose) was superior to 50mg daily for heart failure outcomes, but this higher dosing is not FDA-approved in the US 3
  • European guidelines recommend losartan 50mg as the starting dose with 150mg as the target dose for patients with heart failure 3

Pharmacokinetic Considerations

  • Losartan has a relatively short half-life, but its active metabolite E3174 has a longer half-life of 6-9 hours, providing sustained therapeutic effect 4
  • Studies show that the trough-to-peak ratio for systolic and diastolic responses is 50-95% and 60-90% respectively, supporting once-daily dosing 1
  • A special sustained-release formulation (Losartan Cronos) has been developed specifically to provide 24-hour coverage with once-daily dosing 5

Safety Concerns with Higher Dosing

  • Exceeding FDA-approved dosing may increase the risk of adverse effects such as hypotension, especially in patients with volume depletion 1
  • Dizziness is the most common adverse effect reported with losartan, occurring more frequently than with placebo 6, 7
  • Monitoring for hyperkalemia is important, especially when using higher doses of losartan 2

Clinical Approach

  • If better blood pressure control is needed:
    • Ensure patient is taking the maximum FDA-approved dose of 100mg once daily 1
    • Consider adding a thiazide diuretic (e.g., hydrochlorothiazide 12.5-25mg) which provides additive blood pressure-lowering effects 2, 8
    • If twice-daily dosing is desired for more consistent coverage, split the 100mg total daily dose into 50mg twice daily 2
    • Consider alternative antihypertensive agents from different classes if blood pressure remains uncontrolled on maximum losartan dose plus a diuretic 2

Common Pitfalls to Avoid

  • Exceeding the FDA-approved maximum daily dose of 100mg may increase adverse effects without providing proportional additional benefit 1
  • Combining losartan with ACE inhibitors should be avoided due to increased risk of hyperkalemia and renal dysfunction 3
  • Patients with hepatic impairment require lower dosing (starting at 25mg once daily) 1
  • Losartan should be avoided in pregnancy due to risk of fetal toxicity 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Optimal Dosing of Losartan for Hypertension and Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical pharmacokinetics of losartan.

Clinical pharmacokinetics, 2005

Research

Clinical safety and tolerability of losartan.

Clinical therapeutics, 1997

Research

Efficacy and safety of losartan.

The Canadian journal of cardiology, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.